[Edaily Reporter KIM HYUNSIK ] Plans are underway to produce a new sequel to the "Home Alone" movie series. It has been reported that Hollywood actor Macaulay Culkin (46), who played the lead role of Kevin in the first two films, will also be involved in the production. Macaulay Culkin (Photo: AP)According to foreign media outlets such as the U.S. entertainment publications Variety and Rolling Stone on the 20th (local time), Disney is developing a new sequel to the “Home Alone” series. Culkin is reportedly working on the screenplay alongside actors and producers Seth Rogen and Evan Goldberg. Rogen and Goldberg are also set to serve as producers through their production company, Point Grey. However, the project is in the early stages of development, and no specific plot details or cast have been revealed. It is also unclear whether Culkin will reprise his role as Kevin. Disney has not issued an official statement regarding the reports. “Home Alone” is a comedy film that tells the story of Kevin, a boy left home alone while his family goes on a Christmas trip, who takes on the burglars who break into his house. The first film, released in 1990, grossed approximately $476 million worldwide, and the second installment, released in 1992, grossed approximately $359 million. Culkin gained worldwide fame for his portrayal of Kevin in both films. Subsequent installments followed: the third in 1997, the fourth in 2002, and the fifth in 2012; in 2021, *Home Alone: The Holiday Special* premiered on Disney+. Culkin did not appear in any of the sequels produced after the second film. If Culkin were to participate as an actor in this sequel, it would mark his return to the series for the first time in 34 years, since 1992. At an event last year, Culkin revealed his idea for a sequel featuring an adult Kevin as the protagonist. More recently, he reprised the role of Kevin in a Christmas-themed McDonald’s commercial. However, it remains unknown whether the story Culkin envisioned will actually be incorporated into the sequel.
This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…